Taxotere

Cancer survivors sometimes call Taxotere (docetaxel) “the red devil.” It’s an intravenous drug frequently combined with other chemotherapy medications. Sanofi, the drug’s manufacturer, issued different drug warning labels in the U.S. and Europe. EU literature warned Taxotere patients about permanent hair loss (persistent significant alopecia) risks. American cancer patients weren’t warned about this baldness risk until December 2015. That warning came a full decade after its FDA approval.

Up to 15% of Taxotere patients never re-grow hair anywhere. While temporary hair loss is expected during chemotherapy, this type is permanent. Taxol, a competitor taxane drug, does not cause permanent hair loss. Patients are suing Sanofi for failing to disclose this permanent baldness risk. Further, Taxol is just as effective as killing cancer cells — but these patients weren’t warned or given a choice. Now, they want justice for their unnecessary and permanent disfigurement.

To get contingency-based legal representation claim, fill out our case evaluation form online now. An experienced attorney will contact you to discuss your compensation options.